$AIM
AIM ImmunoTech Inc.

2014 Q4 Form 10-Q Financial Statement

#000094664414000030 Filed on November 07, 2014

View on sec.gov

Income Statement

Concept 2014 Q4 2014 Q3 2013 Q3
Revenue $40.00K $45.00K $36.00K
YoY Change 11.11% 25.0% -7.69%
Cost Of Revenue $330.0K $306.0K $252.0K
YoY Change 106.25% 21.43% -74.49%
Gross Profit -$290.0K -$261.0K -$216.0K
YoY Change 141.67% 20.83% -77.24%
Gross Profit Margin -725.0% -580.0% -600.0%
Selling, General & Admin $1.850M $2.170M $2.070M
YoY Change 5.11% 4.83% 24.7%
% of Gross Profit
Research & Development $2.440M $1.894M $2.173M
YoY Change 59.48% -12.84% -7.81%
% of Gross Profit
Depreciation & Amortization $240.0K $300.0K $200.0K
YoY Change 4.35% 50.0% 5.26%
% of Gross Profit
Operating Expenses $4.280M $1.894M $2.173M
YoY Change 30.09% -12.84% -7.81%
Operating Profit -$4.570M -$4.329M -$4.459M
YoY Change 34.02% -2.92% -10.19%
Interest Expense $250.0K $130.0K $90.00K
YoY Change 47.06% 44.44% -74.29%
% of Operating Profit
Other Income/Expense, Net $10.00K $0.00 $85.00K
YoY Change -93.94% -100.0% -75.43%
Pretax Income -$4.460M -$4.200M -$5.140M
YoY Change 39.38% -18.29% -22.0%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$4.460M -$4.202M -$5.136M
YoY Change 39.59% -18.19% -22.03%
Net Earnings / Revenue -11150.0% -9337.78% -14266.67%
Basic Earnings Per Share
Diluted Earnings Per Share -$11.74M -$11.67M -$16.06M
COMMON SHARES
Basic Shares Outstanding 200.0M shares 190.0M shares 167.4M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2014 Q4 2014 Q3 2013 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $16.11M $17.43M $29.22M
YoY Change -11.43% -40.35% -17.46%
Cash & Equivalents $2.156M $1.262M $1.598M
Short-Term Investments $13.95M $16.17M $27.62M
Other Short-Term Assets $400.0K $240.0K $330.0K
YoY Change 11.11% -27.27% 26.92%
Inventory $0.00 $0.00
Prepaid Expenses $399.0K $235.0K $332.0K
Receivables
Other Receivables
Total Short-Term Assets $16.51M $17.67M $29.55M
YoY Change -11.02% -40.22% -18.92%
LONG-TERM ASSETS
Property, Plant & Equipment $4.601M $4.716M $5.145M
YoY Change -8.95% -8.34% -53.69%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $134.0K $134.0K $136.0K
YoY Change -1.47% -1.47% 94.29%
Total Long-Term Assets $12.93M $12.97M $13.33M
YoY Change -2.87% -2.65% 9.85%
TOTAL ASSETS
Total Short-Term Assets $16.51M $17.67M $29.55M
Total Long-Term Assets $12.93M $12.97M $13.33M
Total Assets $29.44M $30.64M $42.88M
YoY Change -7.62% -28.55% -11.74%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.081M $2.447M $1.723M
YoY Change 63.73% 42.02% -26.37%
Accrued Expenses $2.333M $1.781M $1.822M
YoY Change 89.98% -2.25% 100.22%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $7.050M
YoY Change -100.0% 22.4%
Long-Term Debt Due $20.00K $30.00K $30.00K
YoY Change -33.33% 0.0% -40.0%
Total Short-Term Liabilities $4.436M $4.257M $10.63M
YoY Change 75.2% -59.95% 8.58%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $30.00K
YoY Change -100.0% -100.0% -50.0%
Other Long-Term Liabilities $0.00 $10.00K $70.00K
YoY Change -100.0% -85.71% -96.68%
Total Long-Term Liabilities $0.00 $10.00K $100.0K
YoY Change -100.0% -90.0% -95.39%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.436M $4.257M $10.63M
Total Long-Term Liabilities $0.00 $10.00K $100.0K
Total Liabilities $4.436M $4.273M $10.73M
YoY Change 72.67% -60.17% -10.38%
SHAREHOLDERS EQUITY
Retained Earnings -$277.8M -$273.3M -$257.1M
YoY Change 6.7% 6.3%
Common Stock $302.9M $299.8M $289.4M
YoY Change 4.56% 3.6%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $25.00M $26.37M $32.15M
YoY Change
Total Liabilities & Shareholders Equity $29.44M $30.64M $42.88M
YoY Change -7.62% -28.55% -11.74%

Cashflow Statement

Concept 2014 Q4 2014 Q3 2013 Q3
OPERATING ACTIVITIES
Net Income -$4.460M -$4.202M -$5.136M
YoY Change 39.59% -18.19% -22.03%
Depreciation, Depletion And Amortization $240.0K $300.0K $200.0K
YoY Change 4.35% 50.0% 5.26%
Cash From Operating Activities -$4.030M -$3.720M -$4.020M
YoY Change 26.73% -7.46% 48.89%
INVESTING ACTIVITIES
Capital Expenditures -$190.0K -$180.0K -$270.0K
YoY Change -9.52% -33.33% -84.02%
Acquisitions
YoY Change
Other Investing Activities $2.080M $1.250M $4.590M
YoY Change -77.9% -72.77% -186.6%
Cash From Investing Activities $1.880M $1.070M $4.320M
YoY Change -79.57% -75.23% -161.8%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 3.040M 1.300M -10.00K
YoY Change -144.64% -13100.0% -100.09%
NET CHANGE
Cash From Operating Activities -4.030M -3.720M -4.020M
Cash From Investing Activities 1.880M 1.070M 4.320M
Cash From Financing Activities 3.040M 1.300M -10.00K
Net Change In Cash 890.0K -1.350M 290.0K
YoY Change -212.66% -565.52% -70.71%
FREE CASH FLOW
Cash From Operating Activities -$4.030M -$3.720M -$4.020M
Capital Expenditures -$190.0K -$180.0K -$270.0K
Free Cash Flow -$3.840M -$3.540M -$3.750M
YoY Change 29.29% -5.6% 271.29%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1271000 USD
CY2014Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2447000 USD
CY2014Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1781000 USD
CY2013Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1228000 USD
CY2014Q3 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
1781000 USD
CY2013Q4 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
1228000 USD
CY2014Q3 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
141000 USD
CY2013Q4 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
270000 USD
CY2013Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4334000 USD
CY2014Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4834000 USD
CY2014Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-114000 USD
CY2013Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-114000 USD
CY2013Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
289563000 USD
CY2014Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
299598000 USD
us-gaap Adjustment For Amortization
AdjustmentForAmortization
144000 USD
us-gaap Adjustment For Amortization
AdjustmentForAmortization
414000 USD
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
38421415 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
58129967 shares
CY2014Q3 us-gaap Assets
Assets
30638000 USD
CY2013Q4 us-gaap Assets
Assets
31867000 USD
CY2013Q4 us-gaap Assets Current
AssetsCurrent
18552000 USD
CY2014Q3 us-gaap Assets Current
AssetsCurrent
17666000 USD
CY2013Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
17391000 USD
CY2014Q3 us-gaap Available For Sale Securities
AvailableForSaleSecurities
16169000 USD
CY2013Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
17505000 USD
CY2014Q3 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
16283000 USD
us-gaap Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Aggregate Losses
AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses
0 USD
CY2013 us-gaap Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Aggregate Losses
AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses
0 USD
us-gaap Available For Sale Securities Continuous Unrealized Loss Position Aggregate Losses
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses
126000 USD
CY2013 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Aggregate Losses
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses
229000 USD
CY2014Q3 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
9630000 USD
CY2013Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
12460000 USD
us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Aggregate Losses
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses
126000 USD
CY2013 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Aggregate Losses
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses
229000 USD
CY2014Q3 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
9630000 USD
CY2013Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
12460000 USD
CY2014Q3 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
0 USD
CY2013Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
0 USD
CY2013Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
17391000 USD
CY2014Q3 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
16169000 USD
CY2013 us-gaap Available For Sale Securities Gross Unrealized Gains
AvailableForSaleSecuritiesGrossUnrealizedGains
115000 USD
us-gaap Available For Sale Securities Gross Unrealized Gains
AvailableForSaleSecuritiesGrossUnrealizedGains
0 USD
CY2013 us-gaap Available For Sale Securities Gross Unrealized Loss
AvailableForSaleSecuritiesGrossUnrealizedLoss
229000 USD
us-gaap Available For Sale Securities Gross Unrealized Loss
AvailableForSaleSecuritiesGrossUnrealizedLoss
114000 USD
CY2013Q4 us-gaap Available For Sale Securities Noncurrent
AvailableForSaleSecuritiesNoncurrent
0 USD
CY2014Q3 us-gaap Available For Sale Securities Noncurrent
AvailableForSaleSecuritiesNoncurrent
0 USD
CY2014Q3 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
29000 USD
CY2013Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
33000 USD
CY2013Q4 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
23000 USD
CY2014Q3 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
3000 USD
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
803000 USD
CY2014Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1262000 USD
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2212000 USD
CY2013Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1598000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-614000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
459000 USD
CY2014Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2014Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000 shares
CY2014Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000 shares
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
168660370 shares
CY2014Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
193708424 shares
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
168660370 shares
CY2014Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
193708424 shares
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
168000 USD
CY2014Q3 us-gaap Common Stock Value
CommonStockValue
194000 USD
CY2013Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.03
CY2014Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-4371000 USD
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-12994000 USD
CY2013Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-4139000 USD
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-13078000 USD
CY2014Q3 us-gaap Construction In Progress Gross
ConstructionInProgressGross
7269000 USD
CY2013Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
7046000 USD
CY2013Q3 us-gaap Cost Of Revenue
CostOfRevenue
252000 USD
us-gaap Cost Of Revenue
CostOfRevenue
1078000 USD
us-gaap Cost Of Revenue
CostOfRevenue
923000 USD
CY2014Q3 us-gaap Cost Of Revenue
CostOfRevenue
306000 USD
CY2013Q3 us-gaap Costs And Expenses
CostsAndExpenses
4495000 USD
CY2014Q3 us-gaap Costs And Expenses
CostsAndExpenses
4374000 USD
us-gaap Costs And Expenses
CostsAndExpenses
14683000 USD
us-gaap Costs And Expenses
CostsAndExpenses
13869000 USD
us-gaap Depreciation
Depreciation
500000 USD
us-gaap Depreciation
Depreciation
504000 USD
us-gaap Derivative Gain On Derivative
DerivativeGainOnDerivative
1000 USD
us-gaap Derivative Gain On Derivative
DerivativeGainOnDerivative
229000 USD
CY2013Q3 us-gaap Derivative Gain On Derivative
DerivativeGainOnDerivative
38000 USD
CY2014Q3 us-gaap Derivative Gain On Derivative
DerivativeGainOnDerivative
0 USD
CY2014Q3 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
13000 USD
CY2013Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
14000 USD
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.08
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.07
CY2014Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
CY2014Q3 us-gaap Employee Related Liabilities Current And Noncurrent
EmployeeRelatedLiabilitiesCurrentAndNoncurrent
1438000 USD
CY2013Q4 us-gaap Employee Related Liabilities Current And Noncurrent
EmployeeRelatedLiabilitiesCurrentAndNoncurrent
378000 USD
CY2014Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
301000 USD
CY2013Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
492000 USD
us-gaap Fair Value Assumptions Expected Dividend Payments
FairValueAssumptionsExpectedDividendPayments
0
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
10000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-123000 USD
CY2013 us-gaap Interest Costs Capitalized
InterestCostsCapitalized
143000 USD
us-gaap Interest Expense Lessee Assets Under Capital Lease
InterestExpenseLesseeAssetsUnderCapitalLease
9000 USD
CY2014Q3 us-gaap Interest Expense Lessee Assets Under Capital Lease
InterestExpenseLesseeAssetsUnderCapitalLease
3000 USD
CY2013Q3 us-gaap Interest Expense Lessee Assets Under Capital Lease
InterestExpenseLesseeAssetsUnderCapitalLease
4000 USD
us-gaap Interest Expense Lessee Assets Under Capital Lease
InterestExpenseLesseeAssetsUnderCapitalLease
14000 USD
us-gaap Interest Paid
InterestPaid
-9000 USD
us-gaap Interest Paid
InterestPaid
-144000 USD
CY2014Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
853000 USD
CY2013Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1080000 USD
CY2013Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2070000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5964000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7210000 USD
CY2014Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2174000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1214000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-197000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1573000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
553000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-453000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
0 USD
CY2013Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
0 USD
CY2012Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
453000 USD
CY2014Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
0 USD
CY2013Q4 us-gaap Liabilities
Liabilities
2569000 USD
CY2014Q3 us-gaap Liabilities
Liabilities
4273000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13646000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9931000 USD
CY2013Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4459000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-13755000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-14526000 USD
CY2014Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4329000 USD
CY2014Q3 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
192000 USD
CY2013Q4 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
529000 USD
CY2014Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
134000 USD
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
31867000 USD
CY2014Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
30638000 USD
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2532000 USD
CY2014Q3 us-gaap Liabilities Current
LiabilitiesCurrent
4257000 USD
CY2013 us-gaap Line Of Credit Facility Increase Accrued Interest
LineOfCreditFacilityIncreaseAccruedInterest
130000 USD
us-gaap Line Of Credit Facility Initiation Date1
LineOfCreditFacilityInitiationDate1
2011-07-26
us-gaap Line Of Credit Facility Interest Rate During Period
LineOfCreditFacilityInterestRateDuringPeriod
0.025
us-gaap Nature Of Operations
NatureOfOperations
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Basis Of Presentation</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The consolidated financial statements include the financial statements of Hemispherx Biopharma, Inc. and its wholly-owned subsidiaries. The Company has </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three</font><font style="font-family:inherit;font-size:10pt;"> domestic subsidiaries: BioPro Corp., BioAegean Corp. and Core Biotech Corp., all of which are incorporated in Delaware and are dormant. The Company&#8217;s foreign subsidiary, Hemispherx Biopharma Europe N.V./S.A., established in Belgium in 1998, has minimal activity. All significant intercompany balances and transactions have been eliminated in consolidation. Certain items in these financial statements have been reclassified to conform to the current year presentation. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the opinion of Management, all adjustments necessary for a fair presentation of such consolidated financial statements have been included. Such adjustments consist of normal recurring items. Interim results are not necessarily indicative of results for a full year.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The interim consolidated financial statements and notes thereto are presented as permitted by the Securities and Exchange Commission (&#8220;SEC&#8221;), and do not contain certain information which will be included in the Company&#8217;s annual consolidated financial statements and notes thereto.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These consolidated financial statements should be read in conjunction with the Company&#8217;s consolidated financial statements for the years ended December 31, 2013 and 2012, contained in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2013.</font></div></div>
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-36000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
9739000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
13068000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
651000 USD
CY2013Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
136000 USD
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
0 USD
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-93000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-12994000 USD
CY2013Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
197000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-848000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
0 USD
CY2014Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-169000 USD
us-gaap Other Interest And Dividend Income
OtherInterestAndDividendIncome
624000 USD
CY2014Q3 us-gaap Other Interest And Dividend Income
OtherInterestAndDividendIncome
130000 USD
CY2013Q3 us-gaap Other Interest And Dividend Income
OtherInterestAndDividendIncome
89000 USD
us-gaap Other Interest And Dividend Income
OtherInterestAndDividendIncome
414000 USD
us-gaap Other Than Temporary Impairment Losses Investments Availableforsale Securities
OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities
800000 USD
us-gaap Other Than Temporary Impairment Losses Investments Availableforsale Securities
OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities
0 USD
CY2013Q3 us-gaap Other Than Temporary Impairment Losses Investments Availableforsale Securities
OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities
800000 USD
CY2014Q3 us-gaap Other Than Temporary Impairment Losses Investments Availableforsale Securities
OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities
0 USD
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
184000 USD
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
187000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
747000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
386000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
1222000 USD
us-gaap Profit Loss
ProfitLoss
-12994000 USD
CY2013Q3 us-gaap Profit Loss
ProfitLoss
-5136000 USD
CY2014Q3 us-gaap Profit Loss
ProfitLoss
-4202000 USD
us-gaap Profit Loss
ProfitLoss
-13030000 USD
CY2013Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2014Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2014Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2014Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2013Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2013Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2013Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2014Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2013Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
358000 USD
CY2014Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
235000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
9763000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
14070000 USD
CY2014Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
9550000 USD
CY2013Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
9387000 USD
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5053000 USD
CY2014Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4716000 USD
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
157000 USD
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
36000 USD
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
24000 USD
CY2014Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1894000 USD
CY2013Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2173000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6827000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6550000 USD
CY2014Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-273313000 USD
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-260319000 USD
CY2013Q3 us-gaap Revenues
Revenues
36000 USD
us-gaap Revenues
Revenues
114000 USD
CY2014Q3 us-gaap Revenues
Revenues
45000 USD
us-gaap Revenues
Revenues
157000 USD
CY2014Q3 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
45000 USD
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
114000 USD
CY2013Q3 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
36000 USD
CY2014Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
26365000 USD
CY2013Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
29298000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Method Used
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed
Black-Scholes-Merton
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
9763000 USD
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
260000 USD
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
292000 USD
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
292000 USD
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
260000 USD
CY2014Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
190677576 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
184434475 shares
CY2013Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
167389685 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
167135111 shares
CY2013Q4 heb Accrued Production Cost
AccruedProductionCost
51000 USD
CY2014Q3 heb Accrued Production Cost
AccruedProductionCost
10000 USD
CY2014Q3 heb Availableforsale Securities Continuous Unrealized Loss Position Numberof Securitiesin Loss Position
AvailableforsaleSecuritiesContinuousUnrealizedLossPositionNumberofSecuritiesinLossPosition
1 investment
CY2013Q4 heb Availableforsale Securities Continuous Unrealized Loss Position Numberof Securitiesin Loss Position
AvailableforsaleSecuritiesContinuousUnrealizedLossPositionNumberofSecuritiesinLossPosition
1 investment
CY2013Q3 heb Funds Received From Sale Of Income Tax Net Operating Losses
FundsReceivedFromSaleOfIncomeTaxNetOperatingLosses
0 USD
heb Funds Received From Sale Of Income Tax Net Operating Losses
FundsReceivedFromSaleOfIncomeTaxNetOperatingLosses
686000 USD
heb Otherthan Temporary Impairment Losses Investments Reclassification Adjustment Availableforsale Securities Netof Tax
OtherthanTemporaryImpairmentLossesInvestmentsReclassificationAdjustmentAvailableforsaleSecuritiesNetofTax
0 USD
heb Sharebased Compensation Arrangementby Sharebased Payment Award Optionsand Warrants Grantsin Period Gross
SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsandWarrantsGrantsinPeriodGross
955000 shares
heb Stock Issued For Settlement Of Accounts Payable
StockIssuedForSettlementOfAccountsPayable
38000 USD
CY2013Q3 heb Otherthan Temporary Impairment Losses Investments Reclassification Adjustment Availableforsale Securities Netof Tax
OtherthanTemporaryImpairmentLossesInvestmentsReclassificationAdjustmentAvailableforsaleSecuritiesNetofTax
800000 USD
CY2014Q3 heb Funds Received From Sale Of Income Tax Net Operating Losses
FundsReceivedFromSaleOfIncomeTaxNetOperatingLosses
0 USD
heb Otherthan Temporary Impairment Losses Investments Reclassification Adjustment Availableforsale Securities Netof Tax
OtherthanTemporaryImpairmentLossesInvestmentsReclassificationAdjustmentAvailableforsaleSecuritiesNetofTax
800000 USD
CY2014Q3 heb Otherthan Temporary Impairment Losses Investments Reclassification Adjustment Availableforsale Securities Netof Tax
OtherthanTemporaryImpairmentLossesInvestmentsReclassificationAdjustmentAvailableforsaleSecuritiesNetofTax
0 USD
heb Paymentsfor Office Lease Deposits
PaymentsforOfficeLeaseDeposits
0 USD
heb Paymentsfor Office Lease Deposits
PaymentsforOfficeLeaseDeposits
74000 USD
heb Proceedsfrom Refunded Capital Lease Deposits
ProceedsfromRefundedCapitalLeaseDeposits
3000 USD
heb Proceedsfrom Refunded Capital Lease Deposits
ProceedsfromRefundedCapitalLeaseDeposits
2000 USD
heb Reduction In Wells Fargo Base Rate Percentage
ReductionInWellsFargoBaseRatePercentage
0.0275
heb Funds Received From Sale Of Income Tax Net Operating Losses
FundsReceivedFromSaleOfIncomeTaxNetOperatingLosses
1126000 USD
CY2014Q1 heb Funds Received From Sale Of Income Tax Net Operating Losses
FundsReceivedFromSaleOfIncomeTaxNetOperatingLosses
1126000 USD
heb Inventory Production
InventoryProduction
0 USD
CY2013 heb Inventory Production
InventoryProduction
5000 USD
heb Inventory Spoilage
InventorySpoilage
0 USD
CY2013 heb Inventory Spoilage
InventorySpoilage
458000 USD
heb Issuance Of Common Stock For Accounts Payable And Accrued Expenses
IssuanceOfCommonStockForAccountsPayableAndAccruedExpenses
237000 USD
heb Issuance Of Common Stock For Accounts Payable And Accrued Expenses
IssuanceOfCommonStockForAccountsPayableAndAccruedExpenses
38000 USD
CY2014Q3 heb Margin Account Loan Liability
MarginAccountLoanLiability
0 USD
CY2013Q4 heb Margin Account Loan Liability
MarginAccountLoanLiability
0 USD
heb Number Of Domestic Subsidiaries
NumberOfDomesticSubsidiaries
3 subsidiary
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
dei Document Period End Date
DocumentPeriodEndDate
2014-09-30
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0000946644
CY2014Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
200027874 shares
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
dei Entity Registrant Name
EntityRegistrantName
HEMISPHERX BIOPHARMA INC

Files In Submission

Name View Source Status
0000946644-14-000030-index-headers.html Edgar Link pending
0000946644-14-000030-index.html Edgar Link pending
0000946644-14-000030.txt Edgar Link pending
0000946644-14-000030-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
heb-20140930.xml Edgar Link completed
heb-20140930.xsd Edgar Link pending
heb-2014093010q.htm Edgar Link pending
heb-20140930xex311.htm Edgar Link pending
heb-20140930xex312.htm Edgar Link pending
heb-20140930xex321.htm Edgar Link pending
heb-20140930xex322.htm Edgar Link pending
heb-20140930_cal.xml Edgar Link unprocessable
heb-20140930_def.xml Edgar Link unprocessable
heb-20140930_lab.xml Edgar Link unprocessable
heb-20140930_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending